EPHB2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL589689	0.81	3/20
SCHEMBL588806	0.78	3/20
Dasatinib Anhydrous (SCHEMBL8226)	1.00	2/20
SCHEMBL9423	1.00	2/20
Tivozanib (SCHEMBL172883)	1.00	2/20
Dasatinib Anhydrous (SCHEMBL290515)	1.00	2/20
SCHEMBL588873	0.80	2/20
SCHEMBL588874	0.80	2/20
SCHEMBL231130	0.78	2/20
Tyrphostin Ag-1478 (SCHEMBL93838)	0.73	2/20
SCHEMBL202067	0.72	2/20
SCHEMBL615378	0.68	2/20
SCHEMBL29651	0.67	2/20
SCHEMBL159652	0.65	2/20
SCHEMBL265661	0.64	2/20
SCHEMBL269992	0.64	2/20
SCHEMBL323445	0.64	2/20
SCHEMBL156289	0.64	2/20
Hydrochloric Acid (SCHEMBL263998)	0.63	2/20
SCHEMBL266210	0.62	2/20

Clinical trials — most relevant to EPHB2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	PHASE1/PHASE2	COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer	PHASE2	COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
TORI 104 Pre-Surgical Dasatinib	PHASE2	WITHDRAWN
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing	PHASE1	COMPLETED
Blood Vessel Study	nan	COMPLETED
Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function	nan	COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
The Locus Coeruleus, Norepinephrine and Cognitive Aging	nan	ACTIVE_NOT_RECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
The Role of Gene Changes in Brain Tumor Formation and Growth	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy.	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness	nan	UNKNOWN
Family Blood Pressure Program - GENOA	nan	COMPLETED
Family Blood Pressure Program - SAPPHIRe Network	nan	COMPLETED
Family Blood Pressure Program - HyperGEN	nan	COMPLETED
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers	nan	RECRUITING
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Toxins Removal and Inflammatory State modulAtion During Online Hemodiafiltration: Comparison of Two Different Dialyzers	nan	UNKNOWN
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a EPHB2 binder may also engage these)

Protein	Name	Similarity
Q90344	—	1.000	Q90344 →
Q07498	—	1.000	Q07498 →
Q8CBF3	—	1.000	Q8CBF3 →
Q60629	—	1.000	Q60629 →
P54763	—	1.000	P54763 →
EPHA6	Ephrin type-A receptor 6	1.000	landscape →
P09759	—	1.000	P09759 →
Q91735	—	1.000	Q91735 →
Q07497	—	1.000	Q07497 →
P54757	—	1.000	P54757 →
Q91571	—	1.000	Q91571 →
Q91736	—	1.000	Q91736 →
P54755	—	1.000	P54755 →
EPHA5	Ephrin type-A receptor 5	0.999	landscape →
EPHA3	Ephrin type-A receptor 3	0.999	landscape →
Q62413	—	0.999	Q62413 →
Q03145	—	0.999	Q03145 →
O42422	—	0.998	O42422 →
Q91694	—	0.998	Q91694 →
O08680	—	0.998	O08680 →
Q03137	—	0.997	Q03137 →
P28693	—	0.997	P28693 →
EPHB1	Ephrin type-B receptor 1	0.997	landscape →
P54759	—	0.997	P54759 →
Q1KL86	—	0.996	Q1KL86 →
Q91845	—	0.996	Q91845 →
P54754	—	0.996	P54754 →
P54758	—	0.996	P54758 →
EPHB3	Ephrin type-B receptor 3	0.996	landscape →
P29318	—	0.996	P29318 →